Austin Kirschner, MD, PhD, and colleagues have studied the mechanism of radiation sensitization for enzalutamide using multiple models of human prostate cancer.
News: Translational Research and Interventional Oncology Research Program
A recent study provides clinicians genomic guidance for surveillance of targeted therapy resistance in patients with EGFR-mutant non-small cell lung cancer — and more importantly — another drug option when resistance occurs.
A recent study found that renal cell carcinoma cells with mutations in an enzyme-encoding gene, SETD2, were sensitive to a drug that inhibits the enzyme PI3K-beta.
Vanderbilt researchers have mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.
Drug combinations used for the treatment of non-small-cell lung cancer (NSCLC) and melanoma aren’t as effective as they could be. That could change with a new algorithm developed by a cross-disciplinary Vanderbilt University team for calculating drug synergy.
The American Heart Association (AHA) has issued a scientific statement calling for the integration of cardio-oncology and vascular medicine to provide cancer patients and cancer survivors with optimal cardiovascular care.
Researchers have discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.
As many as 50 percent of stem cell transplant recipients develop diabetes. Brian Engelhardt, M.D., and an interdisciplinary team of experts in diabetes, immunology, endocrine surgery and transplantation are determined to understand why.
Jeremy Warner, MD, MS, associate professor of Medicine and Biomedical Informatics, has been awarded a $1 million grant from the National Cancer Institute to develop software that will help clinicians keep up with the increasing complexity of cancer care.
A recent study shows that a cell receptor, SSTR2, is a candidate biomarker for poor prognosis and a potential therapeutic target for small cell lung cancer.